Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: A cross - sectional study

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Tessema, Belay ^a,c   Biadglegne, Fantahun ^b   Mulu, Andargachew ^a   Getachew, Assefa ^a   Emmrich, Frank ^c,d   Sack, Ulrich ^c,d  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b BAHIR DAR UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVERSE OUTCOME; ARTICLE; ATTITUDE TO ILLNESS; ETHIOPIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MOTIVATION; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; STRUCTURED QUESTIONNAIRE; TREATMENT REFUSAL;

EID: 77649323629     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-7-2     Document Type: Article

References (38)

1. Sandstrom E, Uhnoo I, Ahlqvist-Rastad J, Bratt G, Berglund T, Gisslén M, Lindbäck S, Morfeldt L, Ståhle L, Sönnerborg A, . Swedish Consensus Group Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations. Scand J Infect Dis 2003, 35:155-167. 10.1080/00365540310006395, 12751710, Swedish Consensus Group.
2. UNAIDS/WHO AIDS Epidemic Update December 2005. Geneva 2005, 234-240. UNAIDS/WHO.
3. UNAIDS and World Health Organization AIDS epidemic update. 2003, 123-129. UNAIDS and World Health Organization.
4. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ, . Viral Activation Transfusion Study Investigators Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001, 135:17-26. Viral Activation Transfusion Study Investigators.
5. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD, . EuroSIDA study group Decline in the AIDS and death rates in the Euro SIDA study: an observational study. Lancet 2003, 362:22-29. 10.1016/S0140-6736(03)13802-0, 12853195, EuroSIDA study group.
6. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860. 10.1056/NEJM199803263381301, 9516219.
7. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Bmj 1997, 315:1194-1199. 2127760, 9393221.
8. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622. 10.1056/NEJM199905273402102, 10341273.
9. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L J, Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J, Pomerantz RJ. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Jama 1999, 282:1627-1632. 10.1001/jama.282.17.1627, 10553788.
10. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868. 10.1016/S0140-6736(99)01122-8, 10093977.
11. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the Euro SIDA study. Arch Intern Med 2000, 160:1123-1132. 10.1001/archinte.160.8.1123, 10789605.
12. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489. 10.1126/science.7824947, 7824947.
13. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586. 10.1126/science.271.5255.1582, 8599114.
14. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003, 15:1112-1118.
15. Poppa A, Davidson O, Deutsch J, Godfrey D, Fisher M, Head S, Horne R, Sherr L, . British HIV Association (BHIVA); British Association for Sexual Health and HIV (BASHH) Guidelines on provision of adherence support in individuals receiving ART. 2005, 2:12-19. British HIV Association (BHIVA); British Association for Sexual Health and HIV (BASHH).
16. Ethiopian Ministry of Health Ethiopian monthly antiretroviral treatment report. Addis Ababa (Ethiopia): Ministry of Health 2008, Ethiopian Ministry of Health.
17. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
18. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000, 14:357-366. 10.1097/00002030-200003100-00008, 10770537.
19. Sodergard B. Adherance and readiness to antiretroviral treatment. Acta Universities Upsalinesis. PhD thesis 2006,
20. Gold RS, Hinchy J, Batrouney CG. The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV. Int J STD AIDS 2000, 113:61-70.
21. Machtinger EL, Bangsberg DR. Adherence to HIV Antiretroviral therapy. HIV In sit 2006, 7:16-22.
22. Tadios Y, Davey G. Retroviral drug adherence & its correlates in Addis Ababa, Ethiopia. Ethiop Med J 2006, 44:237-244.
23. Mengesha A, Worku A. Assessment of antiretroviral treatment among HIV infected persons in the Ministry of Defense Hospitals. AAU; MPH Thesis 2005,
24. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Socio demographic and psychological variables influencing adherence to antiretroviral therapy. PMED AIDS 1999, 13:1763-9.
25. Gifford AL, Borman J E, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multi drug antiretroviral regimens. JAIDS 2000, 23:386-95.
26. Bonolo PDF, Casar CC, Acurio FA, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. JAIDS 2006, 19:5-13.
27. Laurent C, Fatou N, Gueye N, et al. Long-term follow up of a cohort of patients on HAART in Senegal (abstract). 10th Conference on Retroviruses & Opportunistic Infections, Boston 2003,
28. Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, Melbourne K, Mitty J, Caro JJ. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther 2000, 22:858-71. 10.1016/S0149-2918(00)80058-2, 10945512.
29. Singh N, Squier C, Sivek M, Wagener M, Nguyen H, Yu VL. Determinants of compliance with HAART therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS 1996, 8:261-269.
30. Pratt R, Robinson N, Loveday HP, Pellowe CM, Franks PJ. Improvement in sexual drive and a falling viral load are associated with adherence to HAART therapy. 12th World AIDS Conference, Geneva Abstract 32343 1998,
31. Catz S, Heckman T, Kochman A. Adherence to HAART therapy among older adults living with HIV disease. 4th International Conference on the Biophysical Aspects of HIV Infection, Canada Ottawa 1999, Poster 18.
32. Buhrich N, Judd FK. HIV and psychiatric disorders. Managing HIV 1997, Sydney: Australasian Medical Publishing Company, Stewart G.
33. Hayman J, Buhrich N. Psychiatric aspects. The AIDS Manual 1994, Sydney: Maclennon & Petty, Gold J, Penny R, Ross M, Morey S, Stewart G, Donovan B, Berenger S.
34. Wright EJ, Brew BJ, Nurrie JN, McArthur JC. HIV-induced neurological disease. Managing HIV 1997, Sydney: Australasian Medical Publishing Company, Stewart G.
35. Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, Inouye J, Henry SB, Nicholas PK, Portillo CJ. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDs 1999, 13:185-197. 10.1089/apc.1999.13.185, 10375267.
36. Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Pat Care STDS 2001, 15:185-91.
37. Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, Friedland G. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005, 17:10-22. 10.1080/09540120412331305098, 15832830.
38. Wagner G, Miller LG. Is the influence of social desirability on patients' self-reported adherence overrated?. J Acquir Immune Defic Syndr 2004, 35:203-204. 10.1097/00126334-200402010-00016, 14722455.